109229
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
免疫治疗晚期食管鳞状细胞癌中炎症和营养标志物的预后价值：一项回顾性队列研究
Authors Liu X, Ren S, Li X, Cheng X, Fang Y, Zhang S, Zhao Y, Ma W, Zhang T
Received 17 June 2025
Accepted for publication 14 October 2025
Published 4 November 2025 Volume 2025:18 Pages 15393—15408
DOI https://doi.org/10.2147/JIR.S547500
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Felix Marsh-Wakefield
Xiaodan Liu,1,* Shengju Ren,1,* Xinyang Li,1 Xiang Cheng,1 Yujing Fang,1 Shuo Zhang,2 Yidi Zhao,2 Wang Ma,1 Tengfei Zhang1,3,4
1Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People’s Republic of China; 2The First Clinical Medical School, Zhengzhou University, Zhengzhou, Henan, People’s Republic of China; 3Medical School, Huanghe Science and Technology University, Zhengzhou, Henan, People’s Republic of China; 4The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Tengfei Zhang, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, People’s Republic of China, Email fcczhangtf@zzu.edu.cn Wang Ma, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, People’s Republic of China, Email doctormawang@126.com
Purpose: This study aimed to evaluate the nutritional, immune, and inflammatory status of esophageal squamous cell carcinoma (ESCC) patients before immunotherapy using blood-based biomarkers, and to develop and validate competing-risk nomogram models to predict overall survival (OS) and progression-free survival (PFS).
Patients and Methods: This retrospective study enrolled 300 ESCC patients who received immunotherapy at the First Affiliated Hospital of Zhengzhou University between January 2021 and December 2023, and randomly assigned them to a primary cohort (210 cases) and a validation cohort (90 cases) at a 7:3 ratio. We screened prognostic factors using least absolute shrinkage and selection operator (LASSO) regression coupled with univariate and multivariate Cox regression analyses to construct a nomogram prediction model. Model validation was performed using the following approaches: (1) Calibration curves were employed to evaluate the agreement between predicted and observed outcomes; (2) Discrimination was assessed through the index of concordance (C-index), time-dependent receiver operating characteristic (ROC) curves, and time-dependent area under the curve (AUC); (3) Clinical utility and predictive accuracy were further assessed using net reclassification improvement (NRI), integrated discrimination improvement (IDI), and decision curve analysis (DCA). Furthermore, the performance of the proposed nomogram was systematically compared with the conventional tumor-node-metastasis (TNM) staging system and another published prediction model.
Results: Through comprehensive multivariate OS analysis conducted in the primary cohort, we established an innovative prognostic nomogram combining systemic immunoinflammatory index (SII) and prognostic nutritional index (PNI). Compared with TNM staging, our model demonstrated strong accuracy, discriminative ability, and clinical utility in the primary and validation cohorts.
Conclusion: This research confirms the prognostic value of SII and PNI in ESCC patients undergoing anti-PD-1 immunotherapy. Given their significant correlation with clinical outcomes, these biomarkers show potential for pretreatment risk assessment in immunotherapy candidates.
Keywords: systemic immunoinflammatory index, prognosis, nomogram, esophageal squamous cell carcinoma, immunotherapy
1Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People’s Republic of China; 2The First Clinical Medical School, Zhengzhou University, Zhengzhou, Henan, People’s Republic of China; 3Medical School, Huanghe Science and Technology University, Zhengzhou, Henan, People’s Republic of China; 4The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Tengfei Zhang, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, People’s Republic of China, Email fcczhangtf@zzu.edu.cn Wang Ma, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, People’s Republic of China, Email doctormawang@126.com
Purpose: This study aimed to evaluate the nutritional, immune, and inflammatory status of esophageal squamous cell carcinoma (ESCC) patients before immunotherapy using blood-based biomarkers, and to develop and validate competing-risk nomogram models to predict overall survival (OS) and progression-free survival (PFS).
Patients and Methods: This retrospective study enrolled 300 ESCC patients who received immunotherapy at the First Affiliated Hospital of Zhengzhou University between January 2021 and December 2023, and randomly assigned them to a primary cohort (210 cases) and a validation cohort (90 cases) at a 7:3 ratio. We screened prognostic factors using least absolute shrinkage and selection operator (LASSO) regression coupled with univariate and multivariate Cox regression analyses to construct a nomogram prediction model. Model validation was performed using the following approaches: (1) Calibration curves were employed to evaluate the agreement between predicted and observed outcomes; (2) Discrimination was assessed through the index of concordance (C-index), time-dependent receiver operating characteristic (ROC) curves, and time-dependent area under the curve (AUC); (3) Clinical utility and predictive accuracy were further assessed using net reclassification improvement (NRI), integrated discrimination improvement (IDI), and decision curve analysis (DCA). Furthermore, the performance of the proposed nomogram was systematically compared with the conventional tumor-node-metastasis (TNM) staging system and another published prediction model.
Results: Through comprehensive multivariate OS analysis conducted in the primary cohort, we established an innovative prognostic nomogram combining systemic immunoinflammatory index (SII) and prognostic nutritional index (PNI). Compared with TNM staging, our model demonstrated strong accuracy, discriminative ability, and clinical utility in the primary and validation cohorts.
Conclusion: This research confirms the prognostic value of SII and PNI in ESCC patients undergoing anti-PD-1 immunotherapy. Given their significant correlation with clinical outcomes, these biomarkers show potential for pretreatment risk assessment in immunotherapy candidates.
Keywords: systemic immunoinflammatory index, prognosis, nomogram, esophageal squamous cell carcinoma, immunotherapy